There is a rapid development of the 'second wave epidemic' of cardiovascular disease that is now flowing through developing countries and the former socialist republics. It is now evident from WHO data that coronary heart disease and cerebrovascular disease are increasing so rapidly that they will rank No. 1 and No. 5 respectively as causes of global burden by the year 2020. In spite of the current low prevalence of hypertensive subjects in some countries, the total number of hypertensive subjects in the developing world is high, and a cost-analysis of possible antihypertensive drug treatment indicates that developing countries cannot afford the same treatment as developed countries. Control of hypertension in the USA is only 20% (blood pressure Ͻ140/90 mm Hg). In Africa only 5-10% have a blood pressure control of hypertension of Ͻ140/90 mm Hg. There are varying responses to antihypertensive therapy in black hypertensive patients. Black
Introduction
A World Health Organisation analysis showed that the prevalence of hypertension in developing countries varied from 1% in some African countries to more than 30% in Brazil. 1 Hypertension is common in the black population of Africa. 2 Throughout subSaharan Africa there is a difference in the prevalence of hypertension between the urban and rural black populations. Blood pressure (BP) assumes much more importance with increasing age. Mortality statistics from six developing countries for 35 to 74-year-olds showed a downward trend in mortality from hypertension and cardiovascular diseases (CVD) in most countries. In spite of the current low prevalence of hypertension in some countries, the total number of hypertensive subjects in the developing world is high, and a cost-analysis of possible antihypertensive drug treatment indicates that developing countries cannot afford the same treatment as developed countries. 1 Our age-corrected prevalence studies showed that in the adult population of Durban, hypertension (WHO criteria) was highest in urban Zulus (25%), intermediate in whites (17.2% ) and lowest in ethni-This will change with the process of acculturation. In a large USA study the prevalence of hypertension was evaluated between 1988 and 1991. The National Health and Nutritional Survey (NHANES) showed that urban black men have a higher prevalence of hypertension compared to urban black females, white males and white females. 8 Thus even in the USA black people have a far higher prevalence of hypertension compared to the Caucasian population. The prevalence of hypertension in black people in the West Indies and in the USA is higher than those in any part of sub-Saharan Africa. This may be because African Americans have been accultured for 300 years, whereas urban Zulus have been accultured only since the turn of the 20th century. It is possible that the BP differences in the time since acculturation may explain the BP differences between African Americans, West Indians, Nigerians and urban Zulus. 3 Accurate national estimates of the prevalence of hypertension in developing countries are lacking. Inadequate funds, inexperience and lack of infrastructure are also important barriers to hypertension research. The Egyptian National Hypertension Project serves as a model for similar studies elsewhere. It addresses a number of Developing countries contribute a greater share to the global burden of cardiovascular disease than the developed countries. 10, 11 Yet it has received less comment and little public health response, even within these countries. In 1990 it has been estimated that 5.3 million deaths were attributable to CVD whereas the corresponding figure for developing countries ranged between 8 to 9 million (ie, relative access of 70%). Regional estimates of CVD mortality indicate that the difference would be even higher if the term 'developed countries' is restricted to established market economies only and excludes the former socialist economies (Table 1) . 10 In 1990 the developing countries contributed 68% of the total global deaths due to non-communicable disease and 63% of the world mortality due to CVD.
12 Table 2 shows the regional contribution to mortality. A greater cause for concern is the early age of CVD in developing countries compared with the developed countries. For example, in 1990, the Another cause for alarm is the projected rise in both proportional and absolute CVD mortality rates in the developing countries over the next 25 years. 13, 14 This is related to the greater life expectancy due to decline in deaths occurring in infancy, childhood, and adolescence and was related to more effective public health responses to perinatal, infectious and nutritional deficiency, social factors like improved female literacy and improved indicators such as per capita income. 15 Adverse lifestyle changes accompanying industrialisation and urbanisation will contribute to the increasing rates of CVD mortality. Salt consumption in Africa has increased. 16 The globalisation of food production and marketing is also contributing to energy-dense foods, poor in dietary fibre and several micronutrients. 17 The 'foetal origins hypothesis' which may lead to glucose intolerance, hypertension and dyslipidaemia in later life and CVD as a consequence, if proved, may be an important risk for CVD because of the vast numbers of poorly nourished infants in developing countries. [18] [19] [20] [21] Tobacco consumption patterns are rising in developing countries in contrast to the overall decline in developed countries. Recent projections from the World Health Organisation suggest that by the year 2020, tobacco will become the largest single cause of death, accounting for 13.3% of global deaths. 22 This paper deals essentially with the black peoples in sub-Saharan Africa. The northern part of Africa has largely non-black populations and this population is not discussed in this paper. There are substantial Asian and white minorities in East and South Africa. The population of South Africa is about 40 million and is growing at the rate of 2.5% per year. The population is 76.2% black, 13.3% white, 8.6% 'mixed' and 2.6% Asian. 23 Coronary heart disease (CHD) is by far the most important cause of death among white and Asians of South Africa in the category of diseases of the circulatory system-and actually the most important of all causes of death. Their total rates of 165.3 and 101.2 per 100 000 respectively, surpass by far that of the 'mixed' group (55.1/100 000) and the black group (5.3 per 100 000). Cerebrovascular disease is first among the 'mixed' group and blacks and second among whites and Asians in the broad category of causes of death. The disease has the highest death rate among the 'mixed' group (80.6) followed by the whites, Asians and then blacks with decreasing rates of 73.6, 62.5 and 36.5 per 100 000. 24 
Determinant factors of hypertension in black subjects
The biochemical differences in black and white subjects is shown in Table 3 . Genetic factors, personal characteristics, autonomic nervous system function, cardiac function, and various environmental factors have been examined in hypertensive black subjects and contrasted with hypertensive whites. Black hypertensive subjects have higher plasma sodium and lower plasma potassium concentrations than normotensives. 25 The hormonal differences between black and white hypertensive subjects is shown in Table 4 . There are also overt differences in potassium transport, which suggest that black people have a more limited capacity to exchange intracellular potassium and that a higher percentage of this exchange is dependent upon oubain-sensitive mechanisms. 26 In the South African black population, red cell magnesium and serum levels of potassium, magnesium and calcium were found to be significantly lower in black hypertensive subjects. 27 Lymphocyte intracellular sodium concentrations were significantly higher in hypertensive, compared with normotens- 28 Black subjects excrete sodium loads more slowly and have a markedly lower rate of urinary kallikrein excretion. 29 Renin is lower in black people and does not increase in response to sodium and volume depletion. 30 Suppression of the renin-angiotensin system has been demonstrated. [31] [32] [33] We have found a higher plasma renin activity (PRA) in rural compared to urban Zulus. This suggests that the cause of a low PRA in black subjects may not be genetic. However, there was no correlation between PRA and urinary sodium, suggesting that dietary sodium was not a factor. There was no correlation between renin and aldosterone in hypertensive urban Zulus, suggesting a defect in the renin-aldosterone in the patients. 34 The lack of stimulation of PRA by natriuresis with furosemide confirmed a hypo-responsive renin-angiotensin system in hypertensive urban Zulus. 27 A hereditary cause for this has been postulated. 35 A difference in salivary Na-K ratios between white and black patients with low-renin essential hypertension has been noted, 36 but daily sodium intake in South African blacks (based on the urinary sodium) was similar to that seen in typical Western diets. 34, 37 A potassium deficient diet as shown by us may play a role in the aetiology of hypertension in South African blacks. 34 Serum angiotensin-converting enzyme (ACE) levels have been studied in black and white normotensive subjects. Renin activity was significantly and inversely associated with systolic and diastolic BP in both black and white subjects. ACE levels, however, were inversely associated with BP in the black subjects but positively associated with BP in the white subjects (P = 0.02) for interaction on diastolic BP, even after adjustment for age, gender, body mass index, alcohol consumption and heart rate. These results suggest that levels of ACE are similar in blacks and whites but their association with BP may possibly reflect underlying ethnic differences in regulation of BP. 38 Socio-economic position has been found to be a major contributor to differences in death rates between black and white men. Differentials in mortality from some specific causes do not simply reflect differentials in income, however, and more detailed investigations are needed of how differences are influenced by environmental exposures, lifetime socio-economic conditions, lifestyle, racism and other socio-cultural and biological factors. 39 The first study to demonstrate familial aggregation of hypertension in black people was that of Miall et al 40 in Jamaica. Obesity is an important cause of hypertension, especially in the urban black women of sub-Saharan Africa. It is more common in urban than in rural Zulu women. 41 In Los Angeles (LA) Campese et al 42 found that the bulk of whites exhibit salt-resistant state and the majority of the blacks have a salt-sensitive state. 42 The Multiple Risk Factor Intervention Trial (MRFIT) study demonstrated that black people had a higher serum creatinine level for the same level of BP than white subjects. 43 From the therapeutic perspective it is important to consider drugs that reduce renal vascular resistance and glomerular pressure such as calcium channel blockers.
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Black patients whose haemodynamic and fluid status are similar to those of their white counterparts tend to have lower heart rates and greater responsiveness to intravascular volume. 44 Changes in peripheral resistance associated with hypertensive heart disease may start in young black men before elevated BP occurs. 45 Adult black subjects with mild hypertension have as much as a two-fold greater prevalence of left ventricular hypertrophy on echocardiography when compared with matched white subjects. 46 A study of black and Indian medical students in Durban, South Africa, showed that black students had higher systolic and diastolic BP throughout the day, night and critical time periods compared with the Indian students. BP load was higher in black (40.8%) than in Indian participants (29.6%) (P Ͻ 0.05) and there was less dipping at night. Left ventricular mass was significantly higher in black than in Indian participants. Risk factors leading to coronary heart disease (CHD) were more common in Indian than in white participants. 47 Thus, qualitative differences exist between black, white and Indian people in respect of the cardiac adaptive process to systemic hypertension. Hypertension is commonly associated with cerebral and aortic atheroma, but CHD is rare in sub-Saharan Africa. Congestive heart failure is common. 48, 49 In contrast in the USA, CHD is common in the African Americans. 50 Serum cholesterol concentration is lower and serum high-density lipoprotein is higher in black compared with the Indian and white people of Durban. 51 Malignant hypertension is common in the black population of sub-Saharan Africa and is an important cause of end-stage renal failure.
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Treatment of hypertension in black subjects
Thiazide diuretics are effective antihypertensive agents in black hypertensive patients and studies suggest that they cause a greater decrease in BP in blacks than in whites. 52, 53 The better hypotensive response in black hypertensive patients is probably due to the fact that, in comparison with whites, more black patients have an expanded intracellular volume and low PRA. In developing countries, in which the majority of black people live, the cost of therapy is important. Because of their low cost, thiazide diuretics are important baseline drugs in the treatment of hypertension. The low incidence of ischaemic heart disease in the black population of Africa 2,48 may mitigate the seriousness of the consequence of the metabolic effects of thiazide diuretics, eg, hyperlipidaemia, and hypokalaemia. The response to antihypertensive agents in black and white communities is shown in Table 5 .
Reserpine or rauwolfia extracts
Reserpine or rauwolfia extracts offer the advantage of low cost, once-daily administration. Side effects like nasal congestion or depression are minimal provided the dosage of reserpine does not exceed 0.1 mg once daily. Reserpine combined with hydrochlorothiazide is as effective as sotalol with hydrochlorothiazide in black patients. 54 In developing countries where the cost of therapy is important, it may be preferable to use a combination of reserpine and hydrochlorothiazide as baseline drugs in hypertension.
Beta-blockers
There are numerous studies that have shown that ␤-blockers are no more effective than placebo in black people. Comparative studies between white and black subjects have shown that white and Indian hypertensive patients respond better to ␤-blockers than black hypertensive patients. Beta-blockers when combined with a thiazide diuretic produce an appreciable hypotensive response in black hypertensive patients. 55 Renin classification does not appear to be instrumental in the initial selection of diuretics or ␤-blockers in the therapy of black hypertensives, but diuresis is more effective. 56 Warren and O'Connor 57 proposed that racial (black/white) differences in clinical severity, haemodynamic profile and response to therapy of essential hypertension may be mediated largely by the vasodilatory and natriuretic renal kallikrein-kinin system. They felt that deficiency in the kallikrein-kinin renal vasodilatory system may explain many of the unique features of essential hypertension in at least some black people, especially older subjects with low PRA. Antihypertensive agents like propranolol, which decrease urinary kallikrein excretion may not be effective in all black subjects. Conversely, if a drug like a thiazide diuretic increases urinary kallikrein in black people, it may have specific advantages in this group of patients.
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Labetalol and carvedilol
These antihypertensive agents block ␣ 1 , ␤ 1 and ␣ 2 adrenergic receptors. They may be more effective than non-selective ␤-blockers in black patients. 58 We have shown that carvedilol, a new non-cardioselective, vasodilating ␤-adrenoceptor blocker, without intrinsic sympathetic activity is an effective agent for treating hypertension in black patients. 59 
Calcium antagonists
Data have shown that black patients, who are prone to a low PRA, respond to calcium channel blockers (CCB). Fadoyami et al, 60 Moser et al, 61 Leary and Asmal, 62 and M'buyamba-Kabangu et al, 63 have shown a good response to CCB in black hypertensive patients. Cruickshank et al 64 found, in their study on the treatment of hypertension in black compared with white non-insulin-dependent diabetics, that ␤-blockers are not effective in treating hypertension in black diabetics. Verapamil was effective although less so than in white patients. The authors conclude that, as yet, no ideal monotherapy exists for hypertension in black diabetic patients. 64 Materson et al 65 found in a randomised doubleblind study of 1292 men with diastolic BP of 95-109 mm Hg that diltiazem ranked first for younger whites and atenolol for older whites. The patients were randomised after a placebo washout period to receive placebo or one of the six drugs: hydrochlorothiazide (12.5-50 mg per day), atenolol (25-100 mg per day), captopril (25-100 mg per day), clonidine (0.2-0.6 mg per day), a sustained-release preparation of diltiazem (120-360 mg per day) or prazosin (4 -20 mg per day). CCB may also have a natriuretic effect and thus lower the BP. A further additive hypotensive effect is achieved when CCBs are combined with a diuretic in black patients.
ACE inhibitors
Studies with ACE inhibitors have shown that in black patients the response is poor. However the response is the same as whites when ACE inhibitors are combined with a low-dose diuretic. ACE inhibitors are effective in black hypertensive patients but in higher doses compared to white and Indian people.
66
Angiotensin II receptor blockers
There is only limited data on the response to angiotensin II (AT 1 ) receptor antagonists in hypertensive blacks. Analysis of the responses in the sub-group of black patients (n = 10-17/study) confirmed that losartan did lower BP in black patients. The magnitude of the fall in black patients appears to be less than in the non-black patients. [67] [68] [69] Data on the newer AT 1 receptor antagonists like candesartan, irbesartan, or valsartan and their efficacy in black hypertensive patients are few in a number of patients.
Elderly black hypertensive patients
The data of Materson et al 65 on elderly patients showed that the best antihypertensive response occurred with diltiazem, followed by hydrochlorothiazide, clonidine and prazosin. Atenolol was only slightly better than placebo and captopril was worse than placebo.
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Diabetic black hypertensive patients ACE inhibitors combined with a small dosage of a thiazide diuretic, for example hydrochlorothiazide 12.5 mg daily, is the treatment of choice. Suitable alternative antihypertensive agents are CCB or ␣-adrenergic blocking agents like prazosin or doxazosin.
Black hypertensive patients with renal disease
The incidence of end-stage renal disease (ESRD) is increasing at the rate of 8-10% per year and poses a major national health problem in the USA. 70 In 1998 nearly 300 000 persons in the USA either underwent dialysis or received a renal transplant for ESRD. 71 Hypertension was found to be the underlying cause in 29% of these patients, second only to diabetes. In black subjects, hypertension was found to be the most common cause of ESRD. This is in contrast to the trend from two major complications of hypertension, myocardial infarction and stroke, both of which decreased in incidence by about 25% in the same decade. 72, 73 The ultimate goal is to prevent renal failure or slow its progression. ACE inhibitors may be more effective than beta-blockers in slowing renal progression. 74 The dihydropyridine CCB's like nifedipine are not as effective as the non-dihydropyridine like verapamil or diltiazem in decreasing proteinuria. 75 Black hypertensive patients respond well to thiazide diuretics, CCB, vasodilators like prazosin, doxazosin, or labetalol (combination of a non-selective ␤-adrenergic blocker and an ␣-␤-blocker). It is suggested that in black hypertensive patients a thiazide diuretic should be added if a ␤-blocker or an ACE inhibitor is used. This is summarised in Table 4 .
Health care and economic consequences
However, in spite of the effective drug therapy available for hypertensive patients in general, economic and social considerations continue to influence the lower rate of detection, treatment and control of hypertension in the black population of the USA with regard to the cost-benefit ratio. We should be cognisant that thiazide diuretics become the baseline therapy of hypertension. 75, 76 We should be aware of the special needs of black patients when initiating therapy. As yet there is no ideal monotherapy in black hypertensive patients. An ideal antihypertensive drug should have not only natriuretic effects, but also the capability to reduce vascular resistance. 77 Whereas the stepped-care treatment of hypertension is widely used, it has become appropriate to consider an individualised patient profile in the treatment of hypertension. 78 Race should constitute an added criterion when an antihypertensive agent is chosen. 54, [79] [80] [81] For regions in which health care resources are particularly scarce, investment in population-based primary prevention strategies may yield the largest benefit. The most cost-effective hypertension treatment programmes will involve the use of lowest cost drugs (eg, diuretics, reserpine, ␤-blockers, generic formulations of ACE inhibitors, angiotensin II antagonists, calcium antagonists, and other generic agents) in the highest risk groups. The selective treatment of patients with pre-existing cardiovascular or renal disease (irrespective of hypertension severity) or with severe hypertension (systolic BP Ͼ180 mm Hg or diastolic BP Ͼ110 mm Hg) will result in the greatest ratio of events prevented to the number of patients treated. 82 The medical and socio-economic consequences of the projected increase in the burden of CVD will be disastrous for the developing countries. The total care for risk factors leading to CVD will be beyond the scope of most developing countries. Expensive investigations and costly drugs may not be available, accessible only to an elite minority. Most developing countries will experience the double burden of pre-transitional diseases (like infections and nutritional diseases) and post-transitional diseases like CVD. Acquired immunodeficiency syndrome (AIDS) will have a major impact on the economy of countries in Southern Africa.
CVD control programmes
The essential components of any CVD programme are: (1) establishment of efficient systems for estimation of CVD-related burden of disease and its secular trends; (2) estimation of the levels of CVD risk for example smoking, elevated cholesterol or blood pressure in representative population samples to identify risk factors that require immediate attention; (3) evaluation of emerging risk factors for example diabetes, obesity, fibrinolytic status, homocysteine that may be of relevance to the population studies; (4) identification of health behaviour determinants that influence the levels of both traditional and emerging risk factors in the context of each society; (5) development of a health policy that will integrate population-based measures of CVD risk modification and cost-effective case management strategies for individuals who have clinically manifested CVD or are detected to be at a high risk of developing it.
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Barriers to prevention policy National policies control of CVD have not yet emerged in developing countries because of: (1) Competing priorities. Infectious and nutritional disorders are still a major health challenge and AIDS takes up a large portion of health resources; (2) Technology-based interventions. This is favoured by policy makers and the media. The proximity of respected clinical cardiologists to policy makers who belong to the social class most affected by CVD often results in iniquitous resource allocation; (3) Inadequate epidemiological data. There is a paucity of reliable data on the burden of the disease and the distribution of risk factors; (4) Poor presentation of message to policy-makers and the media; (5) Discordant messages. False claims are made that risk factors for CVD are not important; (6) Failure to recognise the importance of prevention and costeffectiveness. Many health professionals are unconcerned about preventive action because of the lack of epidemiological orientation during training, pressures of providing health care in crowded clinics and the absence of concern of cost-effectiveness; (7) Anonymity. Health professionals receive no direct recognition for their endeavours from their beneficiaries as they do when providing health care; (8) Economic and social constraints. Dietary advice, although scientifically sound may be irrelevant or impractical for reasons of the availability, affordability and acceptability of foodstuffs; (9) Vested interests. Tobacco and salt companies influence policy makers and the media; (10) Lack of community mobilisation. No concerted efforts have been made to educate the community about the risk factors and dangers of CVD.
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Imperatives of heart health policy
This should consist of: (a) strengthening the epidemiology base; and (b) development of recommendations on cost-effective control. The higher socioeconomic group and the emerging rural elites must be targeted for a population-based approach and involves: (a) lipid screening of adult members of families in whom there is a history of CVD, hypertension, diabetes or persons suspected of having familial hyperlipidaemia; (b) BP measurements in all persons over 30 attending health care facilities and advocacy of self-referral for measurement; (c) clear, target-specific recommendations; (d) dissemination of messages; (e) prioritisation and sequencing. Multiple-risk-factor interventions may not be feasible. Priority should be given to the most costeffective strategy for example tobacco control or non-pharmacological measures for hypertension or hyperlipidaemia; (f) highlighting of cost-effectiveness of lifestyle changes; (g) building coalition of health care professionals and activists. A concerted effort against tobacco, in collaboration with cancer control programmes and a linkage with environmental groups to highlight the deforestation associated with tobacco cultivation and cigarette manufacture is an example of such a group; (h) making education more prevention-oriented; (i) community mobilisation; (j) multi-media campaigns. 83 
Prevention of CVD in Africa
When cardiovascular mortality reached its height in the developed world, the community became more alarmed of its importance. Counselling for lifestyle modification to reduce the risk of cardiovascular disease was more readily accepted. This led to a decrease in cardiovascular mortality in the developed world. In contrast in the developing world the communities are struggling with the burden of pre-transitional and post-transitional disease and the communities are not very aware of the dangers of cardiovascular disease. Moreover the developing world is in a transition of more industrialisation and urbanisation. This increases consumer aspirations which seeks an indulgent lifestyle. It may be difficult to implement moderation in lifestyle.
Strategies to prevent the acquisition or enhancement of CVD risk factors in developing countries (primordial prevention) must be combined to reverse and reduce risk factors elevations in the urban communities (primary prevention). The approach would be non-pharmacological, population based and lifestyle linked. This would obviate the biological and economic costs of a pharmacologic approach.
There is a need to develop cost-effective methods for the diagnosis and low-cost life saving measures for all the risk factors of cardiovascular diseases. Although tertiary care is growing, the pattern should be the optimisation of resources and avoidance of heavy investment in high-cost, low-yield technologies.
